301 related articles for article (PubMed ID: 31076446)
1. Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML.
Garg S; Reyes-Palomares A; He L; Bergeron A; Lavallée VP; Lemieux S; Gendron P; Rohde C; Xia J; Jagdhane P; Müller-Tidow C; Lipka DB; Imren S; Humphries RK; Waskow C; Vick B; Jeremias I; Richard-Carpentier G; Hébert J; Sauvageau G; Zaugg JB; Barabé F; Pabst C
Blood; 2019 Jul; 134(3):263-276. PubMed ID: 31076446
[No Abstract] [Full Text] [Related]
2. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
[TBL] [Abstract][Full Text] [Related]
3. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
Wakita S; Marumo A; Morita K; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Nakayama K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Tashiro H; Sakaguchi M; Yui S; Arai K; Kitano T; Miyata M; Arai H; Kanda M; Itabashi K; Fukuda T; Kanda Y; Yamaguchi H
Cancer Sci; 2023 Apr; 114(4):1297-1308. PubMed ID: 36610002
[TBL] [Abstract][Full Text] [Related]
5. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.
Meyer SE; Qin T; Muench DE; Masuda K; Venkatasubramanian M; Orr E; Suarez L; Gore SD; Delwel R; Paietta E; Tallman MS; Fernandez H; Melnick A; Le Beau MM; Kogan S; Salomonis N; Figueroa ME; Grimes HL
Cancer Discov; 2016 May; 6(5):501-15. PubMed ID: 27016502
[TBL] [Abstract][Full Text] [Related]
6. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
7. CALCRL knockdown suppresses cancer stemness and chemoresistance in acute myeloid leukemia with FLT3-ITD and DNM3TA-R882 double mutations.
Tang S; Zhu H; Sheng L; Mu Q; Wang Y; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Drug Dev Res; 2024 Feb; 85(1):e22137. PubMed ID: 38349260
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.
Loghavi S; Zuo Z; Ravandi F; Kantarjian HM; Bueso-Ramos C; Zhang L; Singh RR; Patel KP; Medeiros LJ; Stingo F; Routbort M; Cortes J; Luthra R; Khoury JD
J Hematol Oncol; 2014 Oct; 7():74. PubMed ID: 25281355
[TBL] [Abstract][Full Text] [Related]
9. [Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Tang SH; Lu Y; Zhang PS; Liu XH; Du XH; Chen D; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Pei RZ; Tang XW
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):552-557. PubMed ID: 30122013
[No Abstract] [Full Text] [Related]
10. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
[TBL] [Abstract][Full Text] [Related]
11. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
[TBL] [Abstract][Full Text] [Related]
12. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
Guryanova OA; Shank K; Spitzer B; Luciani L; Koche RP; Garrett-Bakelman FE; Ganzel C; Durham BH; Mohanty A; Hoermann G; Rivera SA; Chramiec AG; Pronier E; Bastian L; Keller MD; Tovbin D; Loizou E; Weinstein AR; Gonzalez AR; Lieu YK; Rowe JM; Pastore F; McKenney AS; Krivtsov AV; Sperr WR; Cross JR; Mason CE; Tallman MS; Arcila ME; Abdel-Wahab O; Armstrong SA; Kubicek S; Staber PB; Gönen M; Paietta EM; Melnick AM; Nimer SD; Mukherjee S; Levine RL
Nat Med; 2016 Dec; 22(12):1488-1495. PubMed ID: 27841873
[TBL] [Abstract][Full Text] [Related]
13. Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.
Poitras JL; Heiser D; Li L; Nguyen B; Nagai K; Duffield AS; Gamper C; Small D
Oncotarget; 2016 Oct; 7(43):69124-69135. PubMed ID: 27636998
[TBL] [Abstract][Full Text] [Related]
14. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
[TBL] [Abstract][Full Text] [Related]
15. Bone Marrow Clonogenic Myeloid Progenitors from
Guardia RD; González-Silva L; López-Millán B; Rodríguez-Sevilla JJ; Baroni ML; Bueno C; Anguita E; Vives S; Palomo L; Lapillonne H; Varela I; Menendez P
Genes (Basel); 2020 Jan; 11(1):. PubMed ID: 31936647
[TBL] [Abstract][Full Text] [Related]
16. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
[TBL] [Abstract][Full Text] [Related]
17. FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML.
Kivioja J; Malani D; Kumar A; Kontro M; Parsons A; Kallioniemi O; Heckman CA
Sci Rep; 2021 Dec; 11(1):23565. PubMed ID: 34876631
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients.
Chen M; Zeng Z; Li X; Qin W; Cai X; Chen S; Lu X
Int J Lab Hematol; 2023 Dec; 45(6):899-907. PubMed ID: 37519024
[TBL] [Abstract][Full Text] [Related]
19. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T
Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266
[TBL] [Abstract][Full Text] [Related]
20. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
